Essentials of Informed Consent to Psychedelic Medicine.

Area of Science:

• Psychiatry
• Neuroscience
• Mental Health

Background:

• Interest in psychedelic agents for mental health treatment is rapidly increasing.
• Legal reforms and regulatory approvals are accelerating global access to psychedelic medicines.
• US states are enabling supervised psychedelic use outside traditional healthcare settings.

Purpose of the Study:

• To address the lagging standards in integrating psychedelics into healthcare, particularly informed consent processes.
• To identify essential components for informed consent tailored to psychedelic administration in non-research settings.
• To propose sample language and procedures to bridge the gap in current informed consent documents.

Main Methods:

• Analysis of challenges in designing and implementing psychedelic informed consent practices.
• Identification of 7 essential components for psychedelic informed consent.
• Review of existing informed consent documents for psychedelic clinical trials.

Main Results:

• Informed consent for psychedelics is complex due to unique administration features and potential effects.
• Key components include risks of perceptual disturbances, personality changes, altered beliefs, and practitioner disclosures.
• Existing clinical trial consent forms often neglect or underemphasize these critical elements.

Conclusions:

• There is an unmet need for informed consent processes specific to psychedelic therapy outside research.
• Standardized guidelines are necessary to ensure patient safety and understanding.
• Proposed language and procedures can enhance informed consent for psychedelic treatments.